Trials / Completed
CompletedNCT03836924
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety & Efficacy of Perampanel in Indian Patients as An Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Patients With Epilepsy Aged 12 Years or Older
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | Perampanel tablets. |
Timeline
- Start date
- 2019-02-18
- Primary completion
- 2020-03-01
- Completion
- 2020-03-01
- First posted
- 2019-02-11
- Last updated
- 2021-02-18
Locations
12 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03836924. Inclusion in this directory is not an endorsement.